Multicomponent gene therapy vaccines for lung cancer: Effective eradication of established murine tumors in vivo with interleukin-7/herpes simplex thymidine kinase-transduced autologous tumor and ex vivo activated dendritic cells

Gene Therapy

Volumn 4, Issue 12, 1997, Pages 1361-1370

  Sharma, S ^a   Miller, P W ^a   Stolina, M ^a   Zhu, L ^a   Huang, M ^a   Paul, R W ^b   Dubinett, S M ^a,c  

^a Department of Medicine   (United States)

^b Targeted Genetics Corporation   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dendritic cells; Gene therapy; Interleukin 7; Lung cancer

Indexed keywords

CANCER VACCINE; GANCICLOVIR; HYGROMYCIN; INTERLEUKIN 7; THYMIDINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; FEMALE; GENE THERAPY; GENETIC TRANSDUCTION; HERPES SIMPLEX VIRUS; LUNG ALVEOLUS CELL CARCINOMA; LUNG CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS;

ANIMALIA; HERPES; MURINAE; SIMPLEXVIRUS; UNIDENTIFIED RETROVIRUS;

EID: 0031450504     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300531     Document Type: Article

References (67)

1. Johnson BE, Johnson DH (eds). Lung Cancer. Wiley-Liss: New York, 1995.
2. Grim J et al. Induction of apoptotic cell death in erbB-2 overexpressing turner cells of diverse histologic subtypes mediated by intracellular localization of an anti-erbB-2 SFV. Cancer Gene Ther 1994; 1: 333-334 (Abstr. V-100).
3. Smith MJ et al. Surfactant protein A-directed toxin gene kills lung cancer cells in viltro. Hum Gene Ther 1994; 5: 29-35.
4. Tang D-C, Carbone DP. Potential application of gene therapy to lung cancer. Semin Oncol 1993; 20: 368-373.
5. Dubinett SM, Kradin RL. Cytokine immunotherapy of nonsmall cell lung cancer. Regional Immunol 1993; 5: 232-242.
6. Kradin RL, Boyle LA Prefier FI et al. Tumor-derived interteukin-2-dependent lymphocytes in adoptive immunotherapy of lung cancer. Cancer Immunol Immunother 1987; 24: 76-85.
7. Kradin RL, Kurnick JT, Lazarus DS et al. Tumor-infiltrating lymphocytes and interleukin-2 in the treatment of patients with advanced cancer. Lancet 1989; i: 577-580.
8. Yoshino I, Yano T, Murata M et al. Tumor-reactive T cells accumulate in lung cancer tissues but fail to respond due to tumor cell-derived factor. Cancer Res 1992; 52: 775-781.
9. Anderson TM et al. Effects of systemic recombinant interleukin-2 on natural killer and lymphokine activated killer activity of human tumor-infiltrating lymphocytes. Cancer Res 1988; 48: 1180-1183.
10. Huang M et al. Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res 1995; 55: 3847-3853.
11. Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 1995; 13: 399-415.
12. Restifo NP et al. Identification of human cancers deficient in antigen processing. J Exp Med 1993; 177: 265-272.
13. Miller AR el al. Transduction of human melanoma cell lines with the human interleukin-7 gene using retrovirus-mediated gene transfer: comparison of immunological properties with IL-2. Blood 1993; 82: 3686-3694.
14. Dubinett S et al. Down-regulation of murine fibrosarcoma transforming growth factor-βl expression by interleukin-7. J Natl Cancer lnst 1995; 87: 593-597.
15. Sharma S et al. Interleukin-7 gene transfer in non-small cell lung cancer decreases tumor proliferation, modifies cell surface molecule expression, and enhances antitumor reactivity. Cancer Gene Ther 1996; 3: 302-313.
16. Sharma S et al. IL-7 gene transfer enhances Fas-mediated apoptotic cell death in non-small cell lung cancer. Cancer Gene Ther 1995; 2: 312 (Abstr: P-14).
17. Steinman R. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271-296.
18. Huang AYC et al. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994; 264: 961-965.
19. Gabrilovich DI et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nature Med 1996; 2: 1096-1103.
20. Moolten FL. Drug sensitivity ('suicide') genes for selective cancer chemotherapy. Cancer Gene Ther 1994; 1: 279-287.
21. Freeman SM et al. The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-5283.
22. Bi WL, Parysek LM, Warnick R, Stambrook PJ. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSVtk retroviral gene therapy. Hum Gene Ther 1993; 4: 725-731.
23. Elshami AA et at. Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro Gene Therapy 1996; 3: 85-92.
24. Parks G, Duke G, Palmenberg A. Encephalomyocarditis virus 3C protease: efficient cell-free expression from clones which link viral 5' noncoding sequences to the P3 region. J Virol 1986; 60: 376-384.
25. Rizk N et al. Evaluation of the bystander effect in adenovirusmediated p53 gene therapy. Cancer Gene Ther 1996; 3: S36.
26. Marini FC, Nelson JA, Lapeyre J-N. Assessment of bystander effect potency produced by intratumoral implantation of HSVtk-expressing cells using surrogate marker secretion to monitor tumor growth kinetics. Gene Therapy 1995; 2: 655-659.
27. Hock H, Dorsch M, Diamantstein T, Blankenstein T. Interleukin-7 induces CD4 T cell-dependent tumor rejection. J Exp Med 1991; 174: 1291-1298.
28. McBride WH et al. Genetic modification of a murine fibrosarcoma to produce IL-7 stimulates host cell infiltration and tumor immunity Cancer Res 1992; 52: 3931-3937.
29. Alderson MR, Tough TW, Ziegler SF, Grabstein KH. Interleukin-7 induces cytokine secretion and tumoricidal activity by human peripheral blood monocytes. J Exp Med 1991; 173: 923-930.
30. Dubinett S. The immune response of lung tumors and the effects of cytokine administration on pulmonary immune cells. In. Kradin R, Robinson B (eds). Immunopathology of Lung Disease. Butterworth-Heinemann: Boston, 1996, pp 469-490.
31. Smith DR et al. Production of interleukin-10 by human bronchogenic carcinoma. Am J Pathol 1994; 145: 18-25.
32. Anderson TM, Ibavashi Y, Holmes EC, Golub SH. Modification of natural killer activity of lymphocytes infiltrating human lung cancers. Cancer Immunol Immunother 1987; 25: 65-68.
33. Tepper R, Mule J. Experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther 1994; 5: 153-164.
34. Namen A et al. Stimulation of B-cell progenitors by cloned murine interleukin-7. Nature 1988; 333: 571-573.
35. Welch PA et al. Human IL-7: a novel T cell growth factor. J Immunol 1989, 143: 3562-3567.
36. Chazen GD et a7 Interleukin-7 is a T cell growth factor. Proc Natl Acad Sci USA 1989; 86: 5923-5927.
37. Jicha DL, Mule JJ, Rosenberg SA. Interleukin-7 generates antitumor cytotoxic T lymphocytes against murine sarcomas with efficacy in cellular adoptive immunotherapy. J Exp Med 1991; 174: 1511-1515.
38. Stotter H et al. IL-7 induces human lymphokine-activated killer cell activity and is regulated by IL-4. J Immunol 1991; 146: 150-155.
39. Yssel H, Schneider P, Lanier L. Interleukin-7 specifically induces the B7/BB1 antigen on human cord blood and peripheral blood T cells and T cell clones. Int Immunol 1993; 5: 753-759.
40. Azuma M et al. Functional expression of B7/BB1 on activated T lymphocytes. J Exp Med 1993; 177: 845-850.
41. Mehrotra PT, Grant AJ, Siegel JP. Synergistic effects of IL-7 and IL-12 on human T cell activation. J Immunol 1995; 154: 5093-5102.
42. Sieling PA et al. IL-7 in the cell-mediated immune response to a human pathogen. J Immunol 1995; 154: 2775-2783.
43. Kos FJ, Mullbacher A. IL-2-independent activity of IL-7 in the generation of secondary antigen-specific cytotoxic T cell responses in vitro. J Immunol 1993; 150: 387-393.
44. Sica D et al. Interleukin-7 enhances the proliferation and effector function of tumor-infiltrating lymphocytes from renal-cell carcinoma. Int J Cancer 1993; 53: 941-947.
45. Komschlies KL et al. Administration of recombinant human IL-7 to mice alters the composition of B-lineage cells and T cell subsets, enhances T cell function and induces regression of established metastases. J Immunol 1994; 152: 5776-5784.
46. Kelley DM, McBride WH, Dubinett SM. In vivo antitumor response to interleukin-7. Clin Res 1992; 40: 63A.
47. Dubinett SM et al. Down-regulation of macrophage transforming growth factor-β messenger RNA expression by interleukin-7. J Immunol 1993; 151: 6670-6680.
48. Arthur J et al. A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther 1997; 4: 17-25.
49. Inaba K et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophages colony-stimulated factor. J Exp Med 1992; 176: 1693-1702.
50. Mayordomo JI et al. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nature Med 1995; 1: 1297-1302.
51. Zitvogel L et al. Therapy of murine tumors with tumor peptidepulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associa ted cytokines. J Exp Med 1996; 183: 87-97.
52. Celluzzi CM et al. Peptide-pulsed dendritic cells induce antigenspecific, CTL-mediated protective tumor immunity. J Exp Med 1996; 183: 283-287.
53. Boczkowski D, Nair S, Snyder D, Gilboa E Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996; 184: 465-472.
54. Schwartzentruber D, Topalian S, Mancini M, Rosenberg S. Specitic release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha, and IFN-gamma by human tumor-infiltrating lymphocytes after autologous tumor stimulation. J Immunol 1991; 146: 3674-3681.
55. Schwartzentruber D, Stetler-Stevenson M, Rosenberg S, Topalian S. Tumor-infiltrating lymphocytes derived from select B cell lymphomas secrete granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-alpha in response to autologous tumor stimulation. Blood 1993; 82: 1204-1211
56. Yoshino I et al. HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res 1994; 54: 3387-3390.
57. Slingluff CLJ et al. Cytotoxic T lymphocyte response to autologous human squamous cell cancer of the lung: reconstitution with peptides extracted from HLA-Aw68. Cancer Res 1994; 54: 2731-2737.
58. Roth J et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Med 1996; 2: 985-991.
59. Wakimoto H et al. Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4. Cancer Res 1996; 56: 1828-1833.
60. Dilloo D et al. Combined chemokine and cytokme gene transfer enhances antitumor immunity. Nature Med 1996; 2: 1090-1095.
61. Santodonato L et al. Cure of mice with established metastatic Friend leukemia cell tumors by a combined therapy with tumor cells expressing both interferon-α1 and herpes simplex thymidine kinase followed by ganciclovir. Hum Gene Ther 1996; 7: 1-10.
62. Chen S-H et al. Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: sustained antitumor immunity prolongs animal survival. Cancer Res 1996; 56: 3758-3762.
63. Yuhas J, Toya R, Wagner E. Specific and nonspecific stimulation of resistance to the growth and metastasis of the line 1 lung carcinoma. Cancer Res 1975; 35: 242-244.
64. Lupton SD, Brunton LL, Kalberg VA, Overell RW. Dominant positive and negative selection using a hygromycin phospho-transferase-thymidme kinase fusion gene. Mol Cell Biol 1991; 11: 3374-3378.
65. Miller AD, Buttimore C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol 1986; 6: 2895-2902.
66. Bunnak J, Takigami M, Ito H, Shinozawa T. Gamma irradiation effects on cultured cells: investigated by the MTT method. J Rad Res 1994; 35: 205-212.
67. Dubinett SM, Kurnick JT, Kradin RL. Adoptive immunotherapy of murine pulmonary metastases with interleukin 2 and interferon-gamma. Am J Resp Cell Mol Biol 1989; 1: 361-369.